Baxter International Inc. ($BAX) Stock Forecast: Up 5.0% Today

What is Baxter International Inc.?

Baxter International Inc. (BAX) is a healthcare company specializing in medical products for renal care, medication delivery, and pharmaceuticals. Amid a generally negative trading day in the stock market, the company experienced a significant bullish movement.

Why is Baxter International Inc. going up?

BAX stock is up 5.0% on Jun 24, 2026 13:50

• Baxter International Inc. (BAX) demonstrated a 2.24% increase in its stock price, outperforming its industry competitors during a bearish market session.
• The appointment of a new Chief R&D Officer at a competitor in the healthcare sector possibly drew attention to Baxter's innovative capabilities and future growth potential.
• Baxter's release of its 2025 Sustainability Report highlighted its dedication to sustainability and long-term value creation, likely positively influencing investor confidence and perceptions.
• The company's strong performance today can be attributed to its competitive edge, industry advancements, and commitment to sustainable practices, all contributing to a favorable investor outlook.

BAX Price Chart

BAX Technical Analysis

BAX News

Baxter International Inc. stock outperforms competitors on strong trading day

Shares of Baxter International Inc. (BAX) rose 2.24% to $20.10 on Tuesday, despite a generally negative trading session for the broader stock market. The S&P 500 Index (SPX) fell 1.44% and the Dow Jones Industrial Average (DJIA) fell 0.09%. Baxter International Inc. closed 36.70% below its 52-week high.

https://www.marketwatch.com/data-news/baxter-international-inc-stock-outperforms-competitors-on-strong-trading-day-5a29f8bc-c21853519b5e?mod=mw_quote_news

Insulet hires first chief R&D officer amid growing competition

Insulet, a company specializing in insulin patch pumps for diabetes management, has appointed Divakar Ramakrishnan as its first chief research and development officer. This strategic hire aims to bolster Insulet's innovation capabilities and accelerate its pipeline amidst increasing competition in the insulin pump market. Ramakrishnan brings extensive experience from Convatec and Eli Lilly, and will lead global product development for Insulet.

https://www.medtechdive.com/news/insulet-hires-first-chief-rd-officer-amid-growing-competition/823533/

QuidelOrtho Names Micah Young Chief Financial Officer

QuidelOrtho Corporation has appointed Micah Young as Chief Financial Officer, effective July 6, 2026. Young, who previously served as EVP and CFO at Masimo Corporation, will focus on improving profitability, strengthening cash generation, and driving long-term shareholder value. He succeeds Joseph M. Busky, who will remain in an advisory role during the transition.

https://www.citybiz.co/article/864093/quidelortho-names-micah-young-chief-financial-officer/

Baxter International Inc. stock underperforms Monday when compared to competitors

Shares of Baxter International Inc. (BAX) fell 1.16% on Monday, closing at $19.66. This underperformance occurred on a mixed trading day where the Dow Jones Industrial Average rose and the S&P 500 Index fell. The stock is currently 38.09% below its 52-week high of $31.76.

https://www.marketwatch.com/data-news/baxter-international-inc-stock-underperforms-monday-when-compared-to-competitors-2d2ec82a-806ba0e48f47?mod=mw_quote_news

Baxter Publishes 2025 Sustainability Report Highlighting Refreshed Strategy, Ongoing Commitment to Drive Meaningful Impact

Baxter International Inc. has released its 2025 Sustainability Report, detailing a refreshed strategy and new ambitious targets, including achieving Net-Zero greenhouse gas emissions across Scope 1 and Scope 2 by 2050 and using 100% renewable electricity by 2040. The report highlights the company's progress in sustainable healthcare, climate action, and community engagement, driven by a new Chief Sustainability Officer role and updated governance. This initiative underscores Baxter's commitment to long-term value creation and addressing global challenges, aligning with their mission to save and sustain lives.

https://www.businesswire.com/news/home/20260622741106/en/Baxter-Publishes-2025-Sustainability-Report-Highlighting-Refreshed-Strategy-Ongoing-Commitment-to-Drive-Meaningful-Impact

Trending Today

McCormick & Company Incorporated ($MKC) Stock Forecast: Up 5.5% Today

Stryker Corporation ($SYK) Stock Forecast: Up 5.4% Today

Salesforce.com Inc ($CRM) Stock Forecast: Up 5.3% Today

Applied Materials Inc. ($AMAT) Stock Forecast: Down 6.7% Today

Cisco Systems Inc. ($CSCO) Stock Forecast: Down 5.0% Today

Fastly Inc. ($FSLY) Stock Forecast: Up 6.0% Today

Robinhood Inc. ($HOOD) Stock Forecast: Up 5.9% Today

Shopify Inc. Class A Subordinate ($SHOP) Stock Forecast: Up 5.4% Today

Caterpillar Inc. ($CAT) Stock Forecast: Down 5.1% Today

Lam Research Corporation ($LRCX) Stock Forecast: Down 5.3% Today

Baxter International Inc. Price History

17.05.2026 - BAX Stock was down 5.1%

• Baxter International's stock dropped 1.68% on Tuesday, going against the overall market trend.
• Concerns among investors may have arisen due to the company's recent divestment of its Kidney Care business and its strategic focus on medtech and hospital products to boost profitability.
• Despite positive performances in Advanced Surgery and Healthcare Technology, challenges such as weak core business performance and margin compression from external pressures could have contributed to the stock's decline.
• Uncertainties surrounding Baxter's management of regulatory issues with its Novum infusion pump and its efforts to enhance the balance sheet amidst the competitive healthcare landscape might be influencing the market's reactions.

01.03.2026 - BAX Stock was up 5.1%

• The bullish movement in Baxter International Inc. (BAX) stock can be attributed to the launch of its IV Verify Line Labeling System, showcasing the company's commitment to improving patient safety and nurse productivity in clinical settings.
• The positive market response indicates investor confidence in Baxter's strategic developments and potential for revenue growth in the global intravenous solutions market.
• Despite some recent declines in stock performance, this innovative product launch has reignited investor interest and positioned Baxter International for further market expansion and success in the healthcare industry.

30.03.2026 - BAX Stock was up 5.4%

• Despite reporting a Q1 loss, Baxter International Inc. (BAX) experienced a strong bullish movement in the stock market.
• The bullish trend could be attributed to the company's ability to surpass Wall Street expectations in terms of adjusted earnings per share and revenue.
• Investors may be optimistic about Baxter's strategic initiatives post the Kidney Care divestiture and the company's reiterated full-year guidance, which could indicate stability and growth potential.
• The positive market response to Baxter's financial results suggests that investors are focusing more on the company's long-term outlook and operational performance rather than short-term losses.

30.03.2026 - BAX Stock was up 3.2%

• Despite posting a Q1 loss, Baxter International Inc. experienced a strong bullish movement in the stock market.
• The bullish trend could be attributed to the company's robust sales performance, with revenue exceeding expectations and demonstrating a 5% year-over-year increase.
• Investors may have been encouraged by Baxter's resilience in the face of challenges like higher costs and tariffs, as well as the company's reaffirmation of its full-year guidance and strategic initiatives.
• The market reaction, with the stock soaring 7.6%, indicates investor confidence in Baxter's ability to navigate the medtech market landscape and drive long-term growth.

24.05.2026 - BAX Stock was up 5.0%

• Baxter International Inc. (BAX) demonstrated a 2.24% increase in its stock price, outperforming its industry competitors during a bearish market session.
• The appointment of a new Chief R&D Officer at a competitor in the healthcare sector possibly drew attention to Baxter's innovative capabilities and future growth potential.
• Baxter's release of its 2025 Sustainability Report highlighted its dedication to sustainability and long-term value creation, likely positively influencing investor confidence and perceptions.
• The company's strong performance today can be attributed to its competitive edge, industry advancements, and commitment to sustainable practices, all contributing to a favorable investor outlook.

10.05.2026 - BAX Stock was up 5.1%

• Baxter's bullish movement today can be attributed to the exclusive supply and distribution agreement with MediThinQ for its 3D surgical visualization solution 'SHIYA'. This partnership is seen as a strategic move to enhance Baxter's surgical technology offerings and expand its market presence.
• The increasing demand for home dialysis services could also be positively impacting Baxter's stock, given its involvement in renal products and therapies.
• Ceribell's AI-powered algorithm study showcasing improved patient outcomes in critical care settings might be boosting investor confidence in healthcare companies like Baxter, known for their innovative medical solutions.
• The appointment of Ludwig Hantson, a seasoned biopharmaceutical executive, to Ionis Pharmaceuticals' board could be signaling positive industry sentiment, potentially benefiting other healthcare-related stocks like Baxter.

14.03.2026 - BAX Stock was up 5.6%

• Baxter International Inc. showcased its latest innovations, including the AAT XR spine surgical table and Dynamo Series smart stretcher, at the AORN Global Surgical Conference & Expo. These new products aim to improve efficiency, support safer patient care, and address common challenges faced by healthcare teams in surgical settings.
• The company's stock outperformed competitors on a strong trading day, rising by 2.80%. This positive market reaction could be attributed to investor optimism surrounding Baxter's commitment to evolving its portfolio through collaboration with healthcare professionals and its focus on enhancing efficiency and patient care.
• The emphasis on Baxter's new surgical and patient support products, designed to enhance efficiency, streamline workflows, and improve patient care in operating rooms, likely contributed to the bullish movement in the stock price.
• Overall, the market responded positively to Baxter's innovative product showcase at the conference, reflecting investor confidence in the company's ability to drive growth and address the evolving needs of the healthcare industry.

29.03.2026 - BAX Stock was down 5.6%

• Baxter International Inc. (BAX) stock declined by 2.97% on Tuesday, performing below market indices.
• Analysts predict stagnant year-on-year revenue for Q1 earnings, indicating a slowdown compared to previous periods.
• Challenges in product categories aimed at hospitals and unfavorable comparisons are expected to have a negative impact on revenue.
• BlackRock Inc.'s 6.4% ownership filing in Baxter International Inc. may have affected market sentiment, contributing to the bearish trend.

29.03.2026 - BAX Stock was down 5.3%

• Baxter International Inc. (BAX) stock experienced a strong bearish movement, falling 2.97% to $17.94, underperforming the market indices.
• The stock's underperformance could be attributed to the broader market decline, as both the S&P 500 Index and Dow Jones Industrial Average also saw decreases.
• Despite the company's positive Q1 earnings report and potential for recovery, the market pressures and the stock closing significantly below its 52-week high might have contributed to the bearish movement.
• The filing by BlackRock Inc. showing a 6.4% ownership of Baxter International Inc. shares could also be a factor influencing market sentiment, although not directly causing the bearish movement.

31.02.2026 - BAX Stock was up 5.0%

• Baxter International experienced a bullish movement following the successful launch of its IV Verify Line Labeling System, designed to enhance IV medication accuracy and minimize errors in clinical environments.
• Market response has been positive towards Baxter's efforts to reinforce its infusion therapy ecosystem, as demonstrated by its partnership with Vigilant Software to address compliance issues and streamline nurse operations.
• Despite recent stock declines, investor outlook appears bullish on Baxter's ability to leverage the growing intravenous solutions market with this new technology, contributing to today's positive performance.
• The introduction of this cutting-edge system underscores Baxter's dedication to innovation and patient safety, potentially increasing investor trust and driving the stock's upward momentum amid a day of mixed trading in the broader market.

17.03.2026 - BAX Stock was up 8.2%

• Baxter International Inc. stock witnessed a notable surge today, possibly due to its defensive growth profile and focus on essential hospital products.
• The company's strong position in the healthcare sector, emphasizing its hospital supply advantage, could have attracted investors seeking stability in uncertain economic times.
• With the increasing demand for crucial medical supplies, Baxter International Inc.'s stock performance may be benefiting from the rising need for its products, particularly in the expanding Blood And Blood Components Market.
• The generally positive market outlook towards healthcare stocks, alongside Baxter International Inc.'s robust business model and market positioning, likely played a role in its bullish movement today.

04.05.2026 - BAX Stock was up 5.3%

• Baxter's stock witnessed a bullish movement recently, driven by internal factors like executive stock transactions and equity grants. These actions signal confidence and stability within the company's leadership.
• The launch of the IV Verify Line Labeling System highlights Baxter's ongoing focus on innovation and patient safety, which could attract investor attention and contribute to stock price growth.
• The growth of the refurbished medical equipment industry, with industry leaders like GE HealthCare and Siemens Healthineers, might have positively influenced Baxter's stock performance as part of the broader healthcare sector trend. Investors may see Baxter as well-prepared to capitalize on industry growth and technological advancements.